Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma
NCT ID: NCT02868502
Last Updated: 2016-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2016-09-30
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients will be assigned to the different study groups according to their past ocular history. Interventions are similar to all study group and no medical therapy alteration will be made.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Gonioscopy Assisted Transluminal Trabeculotomy in Patients with Primary Open-angle Glaucoma and Cataract.
NCT06865235
Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and Corvis ST Tonometer
NCT02624427
A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction
NCT02784249
Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents
NCT01456390
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
NCT01443988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Glaucoma is a progressive, potentially blinding disease, in which the only modifiable risk factor in intraocular pressure. In a significant proportion of patients, the disease progresses despite apparent IOP control(1-3).
One factor which may explain some of this discrepancy is a fluctuation of the IOP during the day, which may be missed in a single visit to the ophthalmologist(4). Although this fluctuation depends to some degree on daily biologic rhythms and the specific type of glaucoma, a constant significant factor responsible for this effect is the IOP-dependent changes of body posture, from sitting or standing to lying down(5). Older studies have shown IOP postural changes in the range of 4-6 mmHg(6-8). Seeing how a typical patient may spend as much as a third of his life in the supine position, knowledge of IOP in this position, and its control, are of great importance in decreasing the chance for irreversible optic nerve damage.
Several studies of Liu JH(9-11) have investigated the effect of hypotensive drops on nocturnal IOP. While prostaglandin analogues (PGA) and carbonic anhydrase inhibitors (CAI) seemed to have a significant nocturnal IOP lowering effect, the effect seen with beta blockers and alpha agonists was minimal. Mansouri et al.(12) recently showed that PGA seem to flatten the IOP-related increase when moving from the sitting to the supine position at nocturnal period, without effecting other circadian IOP-related patterns.
Hirooka Kazuyuki investigated the effect of trabeculectomy on the IOP fluctuations caused by postural changes(13-14). He showed that successful trabeculectomy, which didn't require needling, have significantly decreased the posture-induced IOP changes to less than 3 mmHg.
To the best of our knowledge there is no data regarding the effect of glaucoma drainage devices and cyclophotocoagulation on supine IOP.
The purpose of this study is to investigate the effect of different IOP lowering methods, including trabeculectomy, glaucoma drainage devices, cyclophotocoagulation and ocular hypotensive eye-drops on IOP with postural change from the sitting to supine positions in eyes with open-angle glaucoma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia.
IOP measurement in different positions.
Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus
Pneumatonometer
IOP measurement in the sitting position and lateral decubitus
Tonopen XL
IOP measurement in the sitting position and lateral decubitus
ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus
Trabeculectomy
Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.
Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus
Pneumatonometer
IOP measurement in the sitting position and lateral decubitus
Tonopen XL
IOP measurement in the sitting position and lateral decubitus
ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus
Ahmed Glaucoma Valve implantation
Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.
Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus
Pneumatonometer
IOP measurement in the sitting position and lateral decubitus
Tonopen XL
IOP measurement in the sitting position and lateral decubitus
ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus
Cyclophotocoagulation
Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.
Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus
Pneumatonometer
IOP measurement in the sitting position and lateral decubitus
Tonopen XL
IOP measurement in the sitting position and lateral decubitus
ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus
Ocular hypotensive eye drops
Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments.
IOP measurement in different positions.
Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus
Pneumatonometer
IOP measurement in the sitting position and lateral decubitus
Tonopen XL
IOP measurement in the sitting position and lateral decubitus
ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus
Ocular Hypertension
Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg..
IOP measurement in different positions.
Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus
Pneumatonometer
IOP measurement in the sitting position and lateral decubitus
Tonopen XL
IOP measurement in the sitting position and lateral decubitus
ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus
Pneumatonometer
IOP measurement in the sitting position and lateral decubitus
Tonopen XL
IOP measurement in the sitting position and lateral decubitus
ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ocular Hypertension (OHT) patients
* Healthy subjects, without any ocular pathology (except for refraction errors, past cataract surgery, strabismus or amblyopia).
Exclusion Criteria
* Illness effecting episcleral venous pressure, such as superior vena cava syndrome, thyroid eye disease, orbital masses
* Patients who are unable to maintain supine position for 15 minutes
* Corneal abnormalities: epithelial pathologies, corneal infection, corneal erosions, corneal scars, keratoconus, S/P corneal transplantation (lamellar/full thickness)
* Hypersensitivity to oxybuprocaine hydrochloride
18 Years
95 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meir Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Avner Belkin
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Avner Belkin, M.D
Role: PRINCIPAL_INVESTIGATOR
Meir Medical Center
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Schulzer M, Mikelberg FS, Drance SM. Some observations on the relation between intraocular pressure reduction and the progression of glaucomatous visual loss. Br J Ophthalmol. 1987 Jul;71(7):486-8. doi: 10.1136/bjo.71.7.486.
Flammer J, Robert Y, Gloor B. Influence of pindolol and timolol treatment on the visual fields of glaucoma patients. J Ocul Pharmacol. 1986 Fall;2(4):305-11. doi: 10.1089/jop.1986.2.305.
Kidd MN, O'Connor M. Progression of field loss after trabeculectomy: a five-year follow-up. Br J Ophthalmol. 1985 Nov;69(11):827-31. doi: 10.1136/bjo.69.11.827.
Barkana Y, Anis S, Liebmann J, Tello C, Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol. 2006 Jun;124(6):793-7. doi: 10.1001/archopht.124.6.793.
Barkana Y, Gutfreund S. Measurement of the difference in intraocular pressure between the sitting and lying body positions in healthy subjects: direct comparison of the Icare Pro with the Goldmann applanation tonometer, Pneumatonometer and Tonopen XL. Clin Exp Ophthalmol. 2014 Sep-Oct;42(7):608-14. doi: 10.1111/ceo.12272. Epub 2014 Jan 13.
Weber AK, Price J. Pressure differential of intraocular pressure measured between supine and sitting position. Ann Ophthalmol. 1981 Mar;13(3):323-6.
Buchanan RA, Williams TD. Intraocular pressure, ocular pulse pressure, and body position. Am J Optom Physiol Opt. 1985 Jan;62(1):59-62. doi: 10.1097/00006324-198501000-00008.
Yamabayashi S, Aguilar RN, Hosoda M, Tsukahara S. Postural change of intraocular and blood pressures in ocular hypertension and low tension glaucoma. Br J Ophthalmol. 1991 Nov;75(11):652-5. doi: 10.1136/bjo.75.11.652.
Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004 Sep;138(3):389-95. doi: 10.1016/j.ajo.2004.04.022.
Liu JH, Medeiros FA, Slight JR, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology. 2010 Nov;117(11):2075-9. doi: 10.1016/j.ophtha.2010.03.026. Epub 2010 Jul 21.
Tung JD, Tafreshi A, Weinreb RN, Slight JR, Medeiros FA, Liu JH. Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure. BMJ Open. 2012 Aug 23;2(4):e001106. doi: 10.1136/bmjopen-2012-001106. Print 2012.
Mansouri K, Medeiros FA, Weinreb RN. Effect of glaucoma medications on 24-hour intraocular pressure-related patterns using a contact lens sensor. Clin Exp Ophthalmol. 2015 Dec;43(9):787-95. doi: 10.1111/ceo.12567. Epub 2015 Aug 16.
Hirooka K, Takenaka H, Baba T, Takagishi M, Mizote M, Shiraga F. Effect of trabeculectomy on intraocular pressure fluctuation with postural change in eyes with open-angle glaucoma. J Glaucoma. 2009 Dec;18(9):689-91. doi: 10.1097/IJG.0b013e31819c49f4.
Hirooka K, Tenkumo K, Nitta E, Sato S. Correlation between Intraocular Pressure Fluctuation with Postural Change and Postoperative Intraocular Pressure in Relation to the Time Course after Trabeculectomy. J Ophthalmol. 2014;2014:801967. doi: 10.1155/2014/801967. Epub 2014 Jul 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMC-0026-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.